ArticleBMC health services research2026
Availability, prices and affordability of nationally negotiated antidiabetic medicines in China: a national survey.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to investigate the availability, prices, and affordability of nationally negotiated antidiabetic medicines in China.
methodsThis study collected monthly medicine usage data from 2018 to 2023 from the China Medical Economic Information Network (CMEI). The study focused on 12 nationally negotiated antidiabetic medicines included in the 2020 edition of the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance. This study covered 804 public general hospitals in 31 provincial administrative regions in China, among which 537 (66.79%) were tertiary, and 267 (33.21%) were secondary. The adjusted World Health Organization and Health Action International methodology was used to conduct a longitudinal descriptive analysis of the availability and affordability of 12 nationally negotiated antidiabetic drugs in the investigated hospitals. Besides, prices are expressed as the defined daily dose cost (DDDc).
resultsFrom 2018 to 2023, the number of antidiabetic medicines with availability exceeding 50% increased from 1 to 5. The total availability of the 12 medicines was higher in tertiary hospitals than in secondary hospitals. The DDDc of the 12 medicines decreased substantially from baseline, with reduction rates ranging from 22.78% to 90.39%. Affordability improved progressively over the study period, with declines ranging from 43.43% to 97.52%. In 2023, 7 out of the 12 antidiabetic medicines were affordable for the population. However, rural residents had lower affordability of the medicines than urban residents.
conclusionsThe overall availability, affordability and DDDc of 12 nationally negotiated antidiabetic medicines improved from 2018 to 2023. However, the overall availability of most antidiabetic medicines in China remained at a low level (less than 50%). Therefore, further efforts should be made to sufficiently and equally benefit patients with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.